<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686994</url>
  </required_header>
  <id_info>
    <org_study_id>ASC41-104</org_study_id>
    <nct_id>NCT04686994</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics (Biomarkers) of ASC41 Tables in Overweight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gannex Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hunan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gannex Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety, tolerability and compare the&#xD;
      pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese&#xD;
      subjects who have elevated LDL-C .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Actual">February 7, 2021</completion_date>
  <primary_completion_date type="Actual">January 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment 3:1 ratio</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Occurrence of Serious Adverse Event (SAE), Adverse Event (AE) resulting in treatment discontinuation and/or dose reductions, and AE of special interest, from baseline up to 28 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of ASC41</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Evaluate the Area under the plasma concentration versus time curve after multiple oral doses of ASC41 tablets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ASC41</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Evaluate the Peak Plasma Concentration after single and multiple oral doses of ASC41 tablets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of ASC41</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Evaluate the Terminal-Phase Half-Life after single and multiple oral doses of ASC41 tables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of ASC41</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Evaluate the Apparent Systemic Clearance after multiple oral dose of ASC41 tables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of ASC41</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Evaluate the Apparent Systemic Clearance after multiple oral dose of ASC41 tables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ASC41</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Evaluate the Time to reach the maximum plasma concentration after multiple oral doses of ASC41 tables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C and other lipid parameters</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>To evaluate the effect of multiple doses of ASC41 tablets on LDL-C and other lipid parameters (TG, TC, HDL-C, etc.) .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Overweight and Obesity</condition>
  <condition>NAFLD</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>ASC41</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC41 two tablets, once daily, from Day 1 to Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASC41 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ASC41 placebo two tablets, once daily, from Day 1 to Day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC 41</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>ASC41</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC 41 Placebo</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>ASC41 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  23kg/m2 â‰¤ BMI &lt;40kg/m2.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  A history of thyroid disease.&#xD;
&#xD;
          -  A positive HBsAg, HCV Ab and/or HIV Ab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hunan provincial people's hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overweight and Obesity</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>LDL-C</keyword>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

